- Nirvana Life Sciences (NIRV) has announced that its supply agreement with Symeres B.V. has produced its first 20 grams of Psilocybin and 20 grams of Psilocin
- These materials will support the company’s ongoing research and development projects
- Symeres is one of the largest European small molecule CRO & CDMOs
- Nirvana Life Sciences operates in the psychedelics space
- As at 11:34:47 ET Nirvana Life Sciences Inc. (NIRV) was down to $0.60, with a loss of $0.01 or 1.64 per cent
Nirvana Life Sciences Inc. (NIRV) has announced that its supply agreement with Symeres B.V. has produced its first 20 grams of Psilocybin and 20 grams of Psilocin.
These materials will support the company’s ongoing research and development projects.
“We are very pleased to have these materials available as we enter the next phase of research and development.,” stated Sazzad Hossain, Chief Scientific Officer of Nirvana.
“Symeres has the capacity to produce and supply many of the compounds that are essential to our research”.
Symeres is one of the largest European small molecule contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), providing R&D (research and development) services and manufacturing to major pharmaceutical and biotechnology companies around the globe.
Its highly specialized services include integrated small molecule optimization efforts, complex synthetic chemistry, route scouting & drug synthesis up to GMP production, solid-state chemistry and ADME-Tox services.
Nirvana Life Sciences is a company operating in the psychedelics space.
Its business model combines the development of formulations for drug development with the development of laboratory space to support ongoing development and manufacturing.
As at 11:34:47 ET Nirvana Life Sciences Inc. (NIRV) was down to $0.60, with a loss of $0.01 or 1.64 per cent.
